Myelofibrosis market

Jun 10, 2024

Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, Janus kinase (JAK) inhibitors have become the mainstay of pharmacologic therapy for myelofibrosis pati...

Sep 22, 2023

On September 15, the FDA authorized GSK’s oral medication momelotinib, now known as Ojjaara, for the treatment of myelofibrosis in adults with anemia. Myelofibrosis is a disorder where normal bone marrow tissue is slowly substituted by fibrous, scar-like material. It is categorized as a form of chronic leukemia and...

Jul 10, 2019

Myelofibrosis (MF) is a rare type of bone marrow cancer resulting in abnormal functioning of blood-forming cells and fibres. MF belongs to a group of disorders known as myeloproliferative disorders. This condition results in the widespread scarring of bone marrow leading to anaemia decreased count of platelets, and...